BiaCure Therapies — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

BiaCure Therapies is targeting the significant unmet need in onychomycosis treatment with its proprietary BiaPulse™ device. The technology aims to overcome the limitations of current topical and oral therapies—low efficacy and safety concerns—by delivering precise energy to the nail bed. Led by a seasoned CEO with a track record of successful medical device exits, the company is developing a system that includes a reusable energy source and custom, AI-generated 3D applicators tailored to individual patient anatomy. The device is currently under development and not yet available for sale.

DermatologyInfectious Disease

Technology Platform

Patented BiaPulse™ technology delivering targeted High Frequency Energy (HFE) via custom, AI-generated 3D applicators for the non-invasive treatment of onychomycosis.

Opportunities

The primary opportunity is addressing the large unmet need for an effective and safe treatment for over 35 million US patients with onychomycosis, particularly diabetics at higher risk of complications.

A successful device could establish a new standard of care and capture a significant share of the multi-billion dollar global market for this condition.

Risk Factors

Key risks include failure to demonstrate sufficient safety and efficacy in clinical trials for FDA clearance, competition from existing devices and potential new therapies, and challenges in securing insurance reimbursement and driving adoption among physicians for a new procedural treatment.

Competitive Landscape

Competition includes low-efficacy topical antifungals (e.g., Jublia), systemic oral drugs with safety concerns (e.g., terbinafine), and other energy-based medical devices cleared for cosmetic nail improvement or other skin disorders. BiaCure must prove its technology offers superior clinical cure rates for the medical treatment of the infection.

More companies in Small Molecule Drugs →More companies in United States →